Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.
暂无分享，去创建一个
R. Janssen | A. Ribas | G. Daniels | G. Long | M. Milhem | E. Gamelin | C. Lao | M. Barve | T. Medina | M. Shaheen | R. Conry | J. Hunt | E. Abdi | M. Almubarak | B. Xing | C. Hoimes | A. Amin | S. Bishnoi | M. Chisamore | A. Candia